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ABSTRACT
SUMMARY: The rapid spread of the coronavirus disease 2019 (COVID-19) pandemic has shaken hospitals worldwide. Some authors
suggest that neurologic involvement could further complicate the disease. This descriptive study is a cross-sectional review of 103
patients diagnosed with COVID-19 who underwent neuroimaging (of a total of 2249 patients with COVID-19 in our center).
Analyzed variables were neurologic symptoms and acute imaging findings. The most frequent symptoms that motivated neuroimag-
ing examinations were mild nonfocal neurologic symptoms, code stroke (refers to patients presenting with signs and symptoms of
stroke whose hyperacute assessment and care is prioritized), focal neurologic symptoms, postsedation encephalopathy, and seiz-
ures. No cases of encephalitis or direct central nervous system involvement were detected. Thirteen patients presented with acute
ischemic events, and 7, with hemorrhagic events; however, most reported multiple vascular risk factors. Despite the large cohort of
patients with COVID-19, we found a large number of symptomatic patients with negative neuroimaging findings, and no conclusions
can be drawn concerning concrete associations between neuroimaging and COVID-19.
ABBREVIATIONS: COVID-19 ¼ coronavirus disease 2019; RT-PCR ¼ reverse transcription polymerase chain reaction; SARS-COV ¼ Severe Acute Respiratory
Syndrome coronavirus
The coronavirus disease 2019 (COVID-19) pandemic causedby the Severe Acute Respiratory Syndrome coronavirus 2
(SARS-CoV-2) started in Wuhan, China, in December 2019 and
spread rapidly. The current focus is in North America and
Europe, including Spain, and particularly Catalonia, where the vi-
rus has overwhelmed the hospitals and made it one of the most
hard-hit regions of Europe.
The clinical hallmark of the disease is viral pneumonia with
fever and dry cough. Patients can suddenly progress to acute re-
spiratory distress syndrome and, in severe cases, to death due to
respiratory or multiorgan failure. Early publications were cen-
tered on these most salient and emergent aspects of the disease,
mainly respiratory, but later articles suggested different sorts of
neurologic complications.1-5
Proposed mechanisms for neurologic implications include the
following:
• Direct central nervous system spread, based on the known
neurotropism of previous SARS-COV strains, which could
access the CNS via olfactory pathways or the bloodstream,
causing meningitis and encephalitis.4,6 The involvement of
the respiratory center in the brain stem may hypothetically
justify the well-documented rapid respiratory deterioration
with marked hypoxia despite a lack of symptomatic
dyspnea.2,7
• Indirect neurologic involvement due to an excessive systemic
proinflammatory response, which may cause widespread dys-
regulation of homeostasis with coagulopathy and may also
increase the risk of acute cerebrovascular diseases.8,9
• Parainfectious autoimmune-based neurologic complications
such as acute disseminated encephalomyelitis and Guillain-
Barré syndromes, which are recognized complications of mi-
crobial infections.10-12
Several studies have described neurologic symptoms in
patients with COVID-19. These symptoms mainly include dizzi-
ness, headache, ataxia, and confusion.5,7,13 One case report sug-
gested viral meningoencephalitis and ventriculitis with reverse
transcription polymerase chain reaction (RT-PCR) positive for
SARS-CoV-2 in the CSF of a young patient with consciousness
disturbance and seizures.6 Anosmia and dysgeusia, which are
highly prevalent in early infection,14 have been proposed in sup-
port of the hypothesis of CNS spread via the olfactory tract.3
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Cerebrovascular events in patients with COVID-19 have also
been documented; Klok et al15 described 3 cases of acute ischemic
stroke in a cohort of 184 patients (1.6%) in the intensive care
unit, while another preprint article described acute cerebrovascu-
lar accidents (ischemic and hemorrhagic) in 13 patients of 221
(5.9%).16 Finally, some cases of parainfectious autoimmune-
based neurologic manifestations concurrent with active COVID-
19 have been described, including hemorrhagic necrotizing ence-
phalopathy12 and Guillain-Barré syndrome.10,11
To the best of our knowledge, neuroimaging of the disease
has not itself been evaluated to date.
Our objective is to present a large series of patients with
COVID-19 with neurologic symptoms requiring neuroimaging.
MATERIALS AND METHODS
Case Series
This article was revised for publication by the research ethics
committee of our tertiary hospital. The data of the patients were
anonymized for this analysis. The confidential information of
patients was protected in accordance with national and European
Union norms. Nonspecific informed consent to participate in
research projects was obtained from all patients. A waiver of a
specific informed consent was provided by the ethics committee
for this retrospective study.
We performed a retrospective cross-sectional review of
patients admitted to our tertiary care center between March 1
and April 18, 2020, with RT-PCR positive for SARS-CoV-2 in
whom brain neuroimaging was performed.
Eligibility criteria were the following: a positive record of RT-
PCR for SARS-CoV-2; neuroimaging performed, including either
head CT or MR imaging; and 16 years of age or older. Exclusion
criteria were the following: neuroimaging performed .5 days
before diagnosis (based on a median incubation period of
5.1 days17), or low-quality imaging on visual assessment.
Regarding the protocol of our center, the RT-PCR for SARS-
CoV-2 testing was performed if the patient presented with severe
respiratory symptoms (respiratory rate of .30 breaths per mi-
nute, blood oxygen saturation of ,95%, with oxygen adminis-
tered at 35%) or pulmonary infiltrates on x-ray suspicious for
viral pneumonia. Furthermore, PCR testing was also performed
on all inpatients, on patients who fulfilled the criteria for in-hos-
pital admission, on candidates for invasive surgical or interven-
tional procedures, on all hospital personnel with any respiratory
or suspicious symptoms, and finally, on vulnerable populations
such as immunocompromised patients.
The minimum required imaging protocol consisted of head
CT with or without contrast from the cranial base to the apex or
MR imaging, including T1WI, T2WI, T2*WI, DWI, and FLAIR.
Available CTA was also reviewed but not included as an eligibility
criterion.
Variables reviewed included basic demographic and clinical
characteristics, symptoms motivating neuroimaging, and acute
neuroimaging findings.
Reasons for neuroimaging were grouped into 7 categories: 1)
mild nonfocal neurologic symptoms and including symptoms
such as headache, transient mild ataxia, dysarthria, or mild con-
fusion not fulfilling code stroke criteria; 2) activated code stroke/
transient ischemic attack; 3) other focal neurologic symptoms; 4)
traumatic brain injury; 5) postsedation encephalopathy; 6) seiz-
ures; and 7) miscellany.
All imaging studies were independently reviewed by 2 certi-
fied neuroradiologists (P.N.-B. and A.P.-E.). Demographics, clini-
cal characteristics, and neuroimaging indications were extracted
from patients’ clinical histories and neuroimaging. Quality assess-
ment of the images was subjectively performed by both certified
neuroradiologists (P.N.-B. and A.P.-E.). Disagreements were
solved by consensus.
RESULTS
From March 1 to April 1, 2020, a total of 2249 patients with RT-
PCR positive for SARS-CoV-2 were admitted in our center.
During the hospitalization period, 112 of these patients under-
went head neuroimaging (17 head MR imaging, 111 head CT,
and 27 CTA). Of these patients, 9 were excluded (1 with MR
imaging1 CT; 2 with CT1 CTA; 6 with CT), 8 of them because
imaging was performed .5 days before SARS-CoV-2 diagnosis
and 1 because of low-quality imaging (Fig 1). Accordingly, the
final number of participants was 103 (Table 1).
Reasons for neuroimaging matched with neuroimaging find-
ings are summarized in Fig 2 and are presented below by catego-
ries. Specific results in patients with MR imaging only are
presented in Table 2.
Mild Nonfocal Neurologic Symptoms
The most common reason for neuroimaging was a nonspecific
state of headache, mild alteration of consciousness, transitory
dysarthria, or gait abnormality, in 40 patients (4 CT 1 MRI, 2
CT 1 CTA, and 34 CT scans). Neuroimaging showed no acute
findings in 36 patients. Two patients had distal small-vessel acute
infarctions (1 cerebellar, 2 left prefrontal), a single patient had a
FIG 1. Recruitment flow chart.
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left parietal lobar acute hematoma, and another had a basilar tip
aneurysm.
Stroke/TIA
The second most common reason for neuroimaging was an acti-
vated code stroke or transient ischemic attack in 25 patients
(7 CT 1 CTA 1 MRI, 1 CT 1 MRI,
11 CT 1 CTA, and 6 CT scans). We
found 6 acute parenchymal hemato-
mas: 3 deep basal ganglia and 3 lobar.
Large-vessel occlusion was observed
in 8 patients. Included were 3 patients
categorized as having small-vessel
occlusion, 2 acute lacunar infarctions,
and 1 patient with multiple, multi-
territory small distal acute parenchy-
mal infarctions. Finally, 8 patients
had no acute neuroimaging findings.
Focal Neurologic Symptoms
Eleven patients underwent neuro-
imaging for focal neural symptoms
that did not fulfill criteria for code
stroke (2 CT 1 CTA 1 MRI, 1 CT 1
MRI, 1 MRI, 1 CT 1 CTA, and 6 CT
scans). Two patients with known
malignancy had an increase in the
size of previously known brain me-
tastases: One of them presented with
visual field disturbance; the other,
with mild acral paresis. Another
patient with abducens nerve palsy
had a large aneurysm at the origin of
the right posterior-inferior cerebellar
artery. The other 8 patients had no
acute neuroimaging findings: One of
them presented with diplopia, and
the other 7, with mild acral paresis.
Traumatic Brain Injury
Seventeen patients underwent CT for
trauma involving the craniofacial
region. Sixteen had no relevant acute




Five patients underwent CT (1 of them
also with CTA) because of a Glasgow
Coma Scale score below 7. Four of
them were patients with delayed recov-
ery of consciousness after prolonged
sedation in the intensive care unit. One
was a patient with severe respiratory
failure. None had any acute findings on
CT or CTA.
Seizures
Three patients had CT performed due to seizures. None of them
had acute findings. Two of them were known to have had epilep-
togenic lesions: One had chronic calcified neurocysticercosis
lesions, and the other had extensive areas of encephalomalacia
due to a prior cerebrovascular accident. For the 1 patient with no
Table 1: Demographic and imaging technique characteristicsa
All Patients Inpatients Emergency Department
No. 103 64 39
Sex (No.) (%)
Male 63 (61%) 37 (58%) 26 (67%)
Female 40 (39%) 27 (42%) 13 (33%)
Age (yr) 74 (50.2–90) 71.5 (48–90) 75 (30.3–89)
Imaging technique
CT 102 (99%) 63 (98%) 39 (100%)
CTA 25 (24%) 14 (22%) 11 (28%)
MR imaging 16 (16%) 13 (20%) 3 (8%)
a Categoric variables are (No.) (%); age is (median) (fifth to 95th percentile).
FIG 2. Summary of results, including all patients undergoing neuroimaging (MR imaging/CT).
Reasons for neuroimaging are on the y-axis. Neuroimaging findings are color-coded in the
legend. Note that “Mild nonfocal neurologic symptoms” refer to any mild state of altered con-
sciousness, mild transient dysarthria, mild transient gait abnormality, or headache. Lacunar or
small distal cortical infarctions not susceptible to thrombectomy were considered “small-
vessel.”
Table 2: Patients undergoing MR imaging
Reason for MR Imaging No. Findings of MR Imaging No.
Code stroke 8 Acute ischemic (small-vessel) 3
Acute ischemic (large-vessel) 2
Parenchymal hemorrhage 3
Other focal neurologic symptoms 4 Metastasis 2
Aneurysm 1
Normal 1
Mild nonfocal neurologic symptoms 4 Acute ischemic 1
Parenchymal hemorrhage 1
Normal 2
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history of seizures or epileptogenic lesions, neuroimaging find-
ings were normal, and seizures were considered to be related to
carbapenem neurotoxicity, which was administered due to con-
current extended-spectrum b -lactamase Klebsiella pneumoniae
infection.
Miscellaneous Cases
Two isolated miscellaneous cases included a case of COVID-19
initial presentation with Guillain-Barré syndrome and normal
neuroimaging (CT) findings, and a case of Staphylococcus aureus
endocarditis with mycotic aneurysms on CTA.
The above cases include 20 cases of nontraumatic cerebrovascular
accidents, with 3 not presenting as code stroke. Details of cardio-
vascular risk factors in these patients are provided in Table 3. Most
notably, 75% of all patients with a cerebrovascular accident had at
least 1 vascular risk factor, and 61% had at least 2, without consid-
ering age. However, in the case of the 7 patients with parenchymal
hematomas, 3 had no vascular risk factors and were younger than
70 years of age. Moreover, of the 4 patients with lobar hematomas,
none had imaging characteristics or clinical history of cerebral
amyloid angiopathy or any other predisposing factor.
DISCUSSION
We have analyzed one of the largest series of patients with
COVID-19 published to date and focused on those patients with
neurologic symptoms requiring neuroimaging. The patients
included in our analysis presented with a varied spectrum of neu-
roimaging indications and findings. Nevertheless, a large number
of symptomatic patients appeared to have negative neuroimaging
findings.
A causal relationship with COVID-19 infection may be rea-
sonably ruled out in some patients, such as the ones with neuro-
imaging performed because of traumatic brain injury or the case
of bacterial endocarditis. Cases with vague symptoms such as a
mild transitory altered level of consciousness or mild nonspecific
focal neurologic symptoms had mostly normal neuroimaging
results or alternative diagnoses independent of COVID-19, such
as brain metastases and unruptured aneurysms.
Furthermore, 4 patients with encephalopathy
after prolonged sedation had normal neuroi-
maging findings. A nonspecific delay in con-
scious-level recovery is not uncommon in
patients with deep and prolonged sedation,
which many patients with COVID-19 require.
Neuro-imaging is performed in these patients
to rule out other occult complications, which,
in these cases, were indeed ruled out. The
remaining patients, in our opinion, warranting
consideration as possibly related to COVID-19
included 13 patients with acute ischemic
lesions, 7 patients with acute hemorrhagic
lesions (4 lobar and 3 deep basal ganglia), 3
patients with seizures, and 1 patient with
Guillain-Barré syndrome and normal neuroi-
maging findings.
There was a high prevalence of vascular risk
factors among acute ischemic cerebrovascular events. Neverthe-
less, in the case of acute hemorrhagic lesions, several cases had no
previous risk factors. Moreover, as illustrative data, during the
same period, the number of code stroke protocols activated in
our center dropped 30% from the previous year. Of 97 patients
with activated code stroke in this time period, 18 were positive
for SARS-CoV-2 (19%) versus 79 who tested negative. To date,
no reliable data are available on the prevalence of the infection in
the local population.
The neurologic symptoms in patients with COVID-19
described in several articles are nonspecific, and inconclusive for
any underlying organic neurologic damage. These symptoms in-
cluded dizziness, headache, ataxia, and confusion, which are fre-
quent transient symptoms of diverse scenarios such as infections,
prolonged hospitalization periods, and posttreatment or postpro-
cedural states, among others.5,13 A case report suggested viral
meningoencephalitis and ventriculitis in a patient with RT-PCR
positive determination on CSF and negative on the nasopharyn-
geal swab for SARS-CoV-2. This patient presented with nonspe-
cific neurologic symptoms such as consciousness disturbance and
seizures, and imaging findings were not specific.6 Regarding
anosmia and dysgeusia, a pre-peer review study suggested that
non-neural support cells but not sensory neural cells express the
angiotensin-converting enzyme 2 receptor, which is targeted by
the virus. This finding would support the hypothesis that anos-
mia and dysgeusia are merely a peripheral phenomenon.18 As for
acute cerebrovascular events in COVID-19, some considerations
prevent establishing causality based on published studies.15,16
Prior common patient underlying conditions/risk factors that
may cause cerebrovascular events seem overlooked; and risk-
stratified control datasets are not used to robustly confirm a
higher incidence of cerebrovascular events or the real increase of
risk in patients with COVID-19. Finally, parainfectious processes
are thought to be triggered by an immune response, and about
two-thirds of patients have a recent history of viral or bacterial re-
spiratory or gastrointestinal tract infection,19 so it seems perfectly
plausible that SARS-COV-2 may also trigger these kinds of dis-
eases, as is suggested in the literature.10-12
Table 3: Demographic and vascular risk factors in cerebrovascular accidents and
all patients with code stroke
All Code
Stroke and
CVA Ischemic Hematoma Normal
No. 28 13 7 8
Sex (No.) (%)
Male 16 (57%) 7 (54%) 6 (86%) 3 (38%)
Female 12 (43%) 6 (46%) 1 (14%) 5 (63%)
Age (median) (range) (yr) 71 (45–89) 74 (45–89) 68 (49–78) 73.5 (67–77)
Vascular risk factors (No.) (%)
Hypertension 20 (71%) 9 (69%) 4 (57%) 7 (88%)
Hypercholesterolemia 14 (50%) 7 (54%) 2 (29%) 5 (63%)
Diabetes mellitus 9 (32%) 3 (23%) 2 (29%) 4 (50%)
Smoker 2 (7%) 0 1 (14%) 1 (13%)
Atrial fibrillation 2 (7%) 2 (15%) 0 0
At least 1 CV risk factor 21 (75%) 10 (77%) 4 (57%) 7 (89%)
At least 2 CV risk factors 17 (61%) 7 (54%) 3 (43%) 7 (89%)
Note:—CV indicates cardiovascular; CVA, cerebrovascular accident.
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There are several important limitations to this study, mainly
due to the rapid expansion of the disease and the critical situation
of many patients, which requires a reorganization of hospital
resources centered on providing the best possible assistance.
First, despite the relatively large sample of patients with COVID-
19 (2249), only 103 who underwent neuroimaging could be
included in this study. This could be partially explained by the
following: Severely ill patients may not have neurologic symp-
toms or may not be able to undergo imaging; or the concern for
transporting infected patients and contaminating radiology
equipment may prompt a higher threshold for imaging indica-
tions. Second, not all presumably infected patients were tested, so
the number of patients with COVID-19 may be underestimated.
Third, the availability full clinical and follow-up information was
limited, and a complete neurologic examination was not always
performed by an experienced neurologist, meaning that our
results do not represent all the clinical neurologic syndromes
affecting these patients. Nevertheless, despite these limitations,
we believe this local review is relevant mainly because COVID-19
is a global phenomenon and many other centers probably experi-
ence the same hindrance of robust data analysis.
CONCLUSIONS
We have analyzed one of the largest series of patients with
COVID-19 published to the date and focused on those with
neurologic symptoms requiring neuroimaging. We have not
found specific neuroimaging presentations of the virus, and a
large number of symptomatic patients appear to have nega-
tive neuroimaging findings. The well-demonstrated virus-
associated coagulopathy may logically increase the risk of
cerebrovascular events (in our experience possibly more
hemorrhagic), but further studies with risk-stratified control
cohorts are required to determine the real impact. Finally,
autoimmune parainfectious entities seem plausible, as they
are in the context of other infectious processes.
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